Shots:

• The study evaluates elraglusib + folfirinox or losartan in patients with advanced pancreatic cancer across the University of Washington, University of Colorado Denver & Johns Hopkins University. The funding has been provided by Lustgarten Foundation
• The company plans to conduct studies in pediatric patients with refractory tumors for a neuroblastoma-specific clinical program
• Elraglusib is a GSK-3β inhibitor & developed for adults & children with advanced refractory cancers. The company collaborated with investigators at the Dana-Farber Cancer Institute & Brigham and Women’s Hospital for a P-II study to evaluate elraglusib + cytotoxic therapy for advanced salivary gland carcinomas

Ref: Globe Newswire | Image: Crunchbase